3 December 2019 - Aerie Pharmaceuticals today announced that it has submitted the marketing authorisation application for Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% with the EMA. 

Should the application for Roclanda be accepted for review by the EMA, an opinion from the Committee for Medicinal Products for Human Use is expected in approximately 12 months. Roclanda is currently marketed in the United States as Rocklatan.

The submission for Roclanda was predicated on the receipt of a marketing authorisation for Rhokiinsa (netarsudil ophthalmic solution) 0.02%, which the European Commission granted in November 2019. Rhokiinsa is marketed as Rhopressa in the United States.

Read Aerie Pharmaceuticals press release